Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANVAC-V and PANVAC-F with Sargramostim in Metastatic Carcinoma
NCT00088413Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2004
- Primary completion
- Apr 2018
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inalimarev and falimarev in metastatic carcinoma, colorectal cancer (CRC), breast cancer and 1 more, sponsored by National Cancer Institute. Primary endpoints: Number of Participants With Complete Responses (CRs), Partial Responses (PRs,) Stable Disease and Progressive Disease at 6 months and Percentage of Vaccines Associated With Grade 1 and Grade 2 Adverse Events Related to Vaccine at 6 months. Started Jul 2004; status: completed.
02
Drugs
inalimarevfalimarev
03
Conditions
metastatic carcinomacolorectal cancer (CRC)breast cancerovarian cancer
Beyond the preview
Go deeper on NCT00088413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088413.